WO2009008009A4 - Novel crystalline form b of carvedilol dihydrogen phosphate - Google Patents
Novel crystalline form b of carvedilol dihydrogen phosphate Download PDFInfo
- Publication number
- WO2009008009A4 WO2009008009A4 PCT/IN2008/000441 IN2008000441W WO2009008009A4 WO 2009008009 A4 WO2009008009 A4 WO 2009008009A4 IN 2008000441 W IN2008000441 W IN 2008000441W WO 2009008009 A4 WO2009008009 A4 WO 2009008009A4
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- process according
- crystalline form
- dihydrogen phosphate
- carvedilol dihydrogen
- range
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
A novel crystalline form B of carvedilol dihydrogen phosphate having X-ray diffraction pattern as shown in figure 1. A process for the preparation of crystalline form B of carvedilol dihydrogen phosphate according to claim 1 that comprises dissolving carvedilol base in aprotic polar solvent, addition of phosphoric acid, heating the solution, adding water to hot solution, cooling, and isolation of solid.
Claims
AMENDED CLAIMS received by the International Bureau on 19 December 2008 (19.12.08).
1, A process for the preparation of crystalline form B of oarvedilol dihydrogen phosphate having X~ray diffraction pattern as shown in figure 1, said process comprises of:
(i) dissolving carvedilol base in aprotic polar solvent, (ii) addition of phosphoric acid, (iii) heating the solution, (iv) adding water to hot solution,
(v) cooling, and (vi) isolation of solid.
2, A process according to claim 1 wherein the aprotie solvent is selected from formamide, N,N-dimethyl formamide, N-mcthylpyrrolidine and mixtures thereof, preferably N5N-dimethy1 formamide.
3, A process according to claim 1 wherein heating is carried out at temperature in the range of 40-100 0C, preferably at 50-70 0C and most preferably at 55-60 0C.
4, A process according to claim 1 wherein water is added at temperature in the range of 40-100 °C, preferably at 50-70 0C and most preferably at 55-60 0C.
5. A process according to claim 1 wherein cooling is carried out at temperature in the range of -5 to 3O0C, preferably to 0-100C.
6. A process according to claim 1 wherein the solid is isolated by filtration.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN980/KOL/2007 | 2007-07-11 | ||
| IN980KO2007 | 2007-07-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2009008009A1 WO2009008009A1 (en) | 2009-01-15 |
| WO2009008009A4 true WO2009008009A4 (en) | 2009-03-05 |
Family
ID=39827949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IN2008/000441 WO2009008009A1 (en) | 2007-07-11 | 2008-07-09 | Novel crystalline form b of carvedilol dihydrogen phosphate |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2009008009A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106892858A (en) * | 2015-12-21 | 2017-06-27 | 上海科胜药物研发有限公司 | A kind of carvidilol dihydric phosphate novel crystal forms |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004002419A2 (en) * | 2002-06-27 | 2004-01-08 | Sb Pharmco Puerto Rico Inc. | Carvedilol phosphate salts and/or solvates thereof, correspondinq compositions, and/or methods of treatment |
| EP1991527A2 (en) * | 2006-06-28 | 2008-11-19 | Teva Pharmaceutical Industries Ltd | Polymorphous forms of carvedilol phosphate |
-
2008
- 2008-07-09 WO PCT/IN2008/000441 patent/WO2009008009A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009008009A1 (en) | 2009-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20150053816A (en) | Crystalline form of tenofovir disoproxil and a process for its preparation | |
| CA2615418A1 (en) | A crystalline form of the zoledronic acid, a process to obtain it and the pharmaceutical composition comprising it | |
| MX2007011238A (en) | Method for making 1-substituted 1h-imidazo[4,5-c]quinolin-4-amine compounds and intermediates therefor. | |
| DD231355A5 (en) | PROCESS FOR THE PREPARATION OF NEW 2-PHENYL-UNIDAZOLENE | |
| CN103923140A (en) | Preparation method of acetylisovaleryltylosin tartrate | |
| WO2009008009A4 (en) | Novel crystalline form b of carvedilol dihydrogen phosphate | |
| CN104829590B (en) | Method for purifying trelagliptin | |
| KR20220104751A (en) | (3-Chloro-2-pyridyl) hydrazine synthesis method | |
| CN111303148A (en) | 1-substituted β -carboline derivatives and application thereof | |
| CA2529470A1 (en) | Process for controlling crystal structure of risedronate | |
| CN102336786A (en) | High-efficiency crystallization method of trichlorosucrose | |
| CN111094246A (en) | Method for preparing alkynyl pyridine prolyl hydroxylase inhibitor | |
| CN101100398A (en) | Method for preparing ammonium magnesium phosphate monohydrate slow-release fertilizer | |
| CN109134403B (en) | Preparation method of 2-morpholine ethanesulfonic acid | |
| WO2013124748A4 (en) | Novel polymorphs of azilsartan medoxomil potassium | |
| CN103039718B (en) | Manufacturing method of 8% flavomycin premixing agent | |
| CN102924472B (en) | Preparation method for olanzapine | |
| CN105218554A (en) | The synthesis technique of 4-chlorine pyrrolo-[2,3-D] pyrimidine | |
| DD234012A5 (en) | PROCESS FOR PREPARING NEW IMIDAZOLE DERIVATIVES | |
| DE3224213A1 (en) | SUBSTITUTED PYRROLO- (2,1-B) -QUINAZOLINES AND PYRIDO- (2,1-B) -QUINAZOLINES, METHODS FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS THAT CONTAIN THESE COMPOUNDS | |
| BR112019022073A2 (en) | process for preparing piperazine ring for the synthesis of pyrazinocarbazole derivatives. | |
| WO2010046851A1 (en) | Process for the preparation of 1- ( 3-hydroxymethylpyrid-2 -yl ) -2 -phenyl-4-methylpiperazine and mirtazapine | |
| CN103880846B (en) | A kind of preparation method of triazolo pyrimidine mercapto radical-type compound | |
| WO2007064569A3 (en) | Chromane substituted 2 -alkyl imidazopyridine derivatives and use thereof as acid pump antagonists | |
| CN106749043A (en) | A kind of adenine intermediate pyrimidine azo and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08789915 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 08789915 Country of ref document: EP Kind code of ref document: A1 |